About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Biomedical Research in Urology group is interested in the study of hormone-dependent cancers, in particular prostate cancer (but not limited to it).
Our efforts are focused on finding, on the one hand, tools that help us in the early diagnosis of the disease, in the best differentiation of tumors according to their aggressiveness and their response to therapy, and finally in finding effective therapies against it.
From a molecular point of view, we focus our studies mainly on cell signaling processes related to the cell cycle and mitosis (with kinesins, kinases and ubiquitin ligases as main targets).
Our multidisciplinary group is made up of molecular biologists and urologists, and we collaborate with oncologists, pathologists and specialists in other diseases when required.
We work with in silico data obtained with different "omics" techniques, samples and clinical data from patients, in vitro and in vivo models, to answer the questions raised.
PMID: 34352790 Journal: UROLOGIA INTERNATIONALIS Year: 2022 Reference: Urol Int. 2022;106(2):154-162. doi: 10.1159/000517543. Epub 2021 Aug 5. Impact factor: Publication type: Paper in international publication Authors: Aula Olivar, Ana; Carrion Puig, Albert; De Torres Ramirez, Ines M; Lozano Palacio, Fernando; Raventos Busquets, Carles X; Semidey, M Eugenia; Trilla Herrera, Enrique et al. DOI: 10.1159/000517543
PMID: 35101469 Journal: RADIOTHERAPY AND ONCOLOGY Year: 2022 Reference: Radiother Oncol. 2022 Jan 28. pii: S0167-8140(22)00032-9. doi: 10.1016/j.radonc.2022.01.028. Impact factor: Publication type: Letter or abstract Authors: Morote, Juan et al. DOI: 10.1016/j.radonc.2022.01.028
PMID: 35024631 Journal: European Urology Open Science Year: 2022 Reference: Eur Urol Open Sci. 2022 Jan 3;35:47-53. doi: 10.1016/j.euros.2021.11.005. eCollection 2022 Jan. Impact factor: Publication type: Paper in international publication Authors: Abaza, Ronney; Bonet, Xavier; Breda, Alberto; Carrion, Albert; Eun, Daniel; Gaya, Josep Maria; Guru, Khurshid A; Hosseini, Abolfazl; Hussein, Ahmed Aly; Iqbal, Umar et al. DOI: 10.1016/j.euros.2021.11.005
PMID: 34992001 Journal: European Urology Focus Year: 2022 Reference: Eur Urol Focus. 2022 Sep;8(5):1557-1558. doi: 10.1016/j.euf.2021.12.007. Epub 2022 Jan 3. Impact factor: Publication type: Letter or abstract Authors: Morote, Juan; Planas, Jacques; Trilla, Enrique et al. DOI: 10.1016/j.euf.2021.12.007
On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.
The work led by Dr. Regis demonstrates that performing robotic reconstruction after radical prostatectomy is associated with better urinary control.
A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.
